Evidence map›Paper›PMID 38319325›Full record

ArticleClinical research in cardiology : official journal of the German Cardiac Society2024

Circulating osteoprotegerin as a cardiac biomarker for left ventricular diastolic dysfunction in patients with pre-dialysis chronic kidney disease: the KNOW-CKD study.

Sang Heon Suh, Tae Ryom Oh, Hong Sang Choi, Chang Seong Kim, Eun Hui Bae, Seong Kwon Ma, Kook-Hwan Oh, Ji Yong Jung, Young Youl Hyun, Soo Wan Kim and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sang Heon SuhDepartment of Internal Medicine, Chonnam National University Medical School and Chonnam National University Hospital, 42 Jebongro, Gwangju, 61469, Korea.
Tae Ryom OhDepartment of Internal Medicine, Chonnam National University Medical School and Chonnam National University Hospital, 42 Jebongro, Gwangju, 61469, Korea.
Hong Sang ChoiDepartment of Internal Medicine, Chonnam National University Medical School and Chonnam National University Hospital, 42 Jebongro, Gwangju, 61469, Korea.
Chang Seong KimDepartment of Internal Medicine, Chonnam National University Medical School and Chonnam National University Hospital, 42 Jebongro, Gwangju, 61469, Korea.
Eun Hui BaeDepartment of Internal Medicine, Chonnam National University Medical School and Chonnam National University Hospital, 42 Jebongro, Gwangju, 61469, Korea.
Seong Kwon MaDepartment of Internal Medicine, Chonnam National University Medical School and Chonnam National University Hospital, 42 Jebongro, Gwangju, 61469, Korea.
Kook-Hwan OhDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Ji Yong JungDivision of Nephrology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea.
Young Youl HyunDepartment of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, 03181, Republic of Korea.
Soo Wan KimDepartment of Internal Medicine, Chonnam National University Medical School and Chonnam National University Hospital, 42 Jebongro, Gwangju, 61469, Korea. skimw@chonnam.ac.kr.ORCID http://orcid.org/0000-0002-3540-9004
Korean Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD) Investigators

Funding

by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) RS-2023-00217317the Research Program funded by the Korea Disease Control and Prevention Agency 2011E3300300the Research Program funded by the Korea Disease Control and Prevention Agency 2012E3301100the Research Program funded by the Korea Disease Control and Prevention Agency 2013E3301600the Research Program funded by the Korea Disease Control and Prevention Agency 2013E3301601the Research Program funded by the Korea Disease Control and Prevention Agency 2013E3301602the Research Program funded by the Korea Disease Control and Prevention Agency 2016E3300200the Research Program funded by the Korea Disease Control and Prevention Agency 2016E3300201the Research Program funded by the Korea Disease Control and Prevention Agency 2016E3300202the Research Program funded by the Korea Disease Control and Prevention Agency 2019E320100the Research Program funded by the Korea Disease Control and Prevention Agency 2019E320101the Research Program funded by the Korea Disease Control and Prevention Agency 2019E320102the Research Program funded by the Korea Disease Control and Prevention Agency 2022-11-007
6 · The paper itself

Abstract

backgroundHeart failure with preserved ejection fraction (HFpEF) is a major cause of mortality in patients with chronic kidney disease (CKD), and diagnosis is challenging. Moreover, no specific biomarker for HFpEF has been validated in patients with CKD. The present study aimed to investigate the association between serum osteoprotegerin (OPG) levels and the risk of left ventricular diastolic dysfunction (LVDD), a surrogate of HFpEF, in patients with pre-dialysis CKD.

methodsA total of 2039 patients with CKD at stage 1 to pre-dialysis 5 were categorized into quartiles (Q1 to Q4) by serum OPG levels, and were cross-sectionally analyzed. The study outcome was LVDD, which was operationally defined as the ratio of early transmitral blood flow velocity to early diastolic velocity of the mitral annulus (E/e') > 14.

resultsIn the analysis of baseline characteristics, higher serum OPG levels were clearly related to the risk factors of HFpEF. A scatter plot analysis revealed a moderate correlation between serum OPG levels and E/e' (R = 0.351, P < 0.001). Logistic regression analysis demonstrated that the risk of LVDD in Q3 (adjusted odds ratio 2.576, 95% confidence interval 1.279 to 5.188) and Q4 (adjusted odds ratio 3.536, 95% confidence interval 1.657 to 7.544) was significantly higher than that in Q1.

conclusionsElevated serum OPG levels are associated with the risk of LVDD in patients with pre-dialysis CKD. The measurement of serum OPG levels may help the diagnosis of LVDD, which is an important echocardiographic feature of HFpEF.

Indexed as

BiomarkersOsteoprotegerinRenal Insufficiency, ChronicVentricular Dysfunction, LeftAgedCross-Sectional StudiesDiastoleFemaleHumansMaleMiddle AgedRenal DialysisRisk FactorsStroke VolumeVentricular Function, LeftBiomarkersOsteoprotegerinTNFRSF11B protein, humanBiomarkerChronic kidney diseaseLeft ventricular diastolic dysfunctionOsteoprotegerin

Identifiers

PMID38319325
PMCPMC11493791

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.